Lysates from siRNA-transfected 22Rv1 and VCaP cells were subjected to immunoprecipitation with rabbit antisera raised to the unique AR-V9 COOH-terminal peptide (details in the
Supplementary Methods), a mouse monoclonal antibody specific for the unique AR-V7 COOH-terminal peptide (Cat #: AG10008, Precision Antibody), or rabbit/mouse IgG controls. Immunoprecipitated complexes were boiled in 1X Laemmli buffer and resolved in denaturing gels. Alternatively, transfected cells were harvested in 1X Laemmli buffer and lysates were resolved in denaturing gels. Gels were transferred to nitrocellulose membranes and subjected to western blot analysis as described. Membranes were incubated with primary antibodies (
AR-N20, Santa Cruz;
AR441, Santa Cruz;
ERK2-D2, Santa Cruz) diluted 1:1000 overnight at 4°C and then incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies diluted 1:10,000 at room temperature for 2h. Blots were developed by incubation with Super Signal chemiluminescence reagent (Pierce) and exposed to film.
Kohli M., Ho Y., Hillman D.W., Van Etten J.L., Henzler C., Yang R., Sperger J.M., Li Y., Tseng E., Hon T., Clark T., Tan W., Carlson R.E., Wang L., Sicotte H., Thai H., Jimenez R., Huang H., Vedell P.T., Eckloff B.W., Quevedo J.F., Pitot H.C., Costello B.A., Jen J., Wieben E.D., Silverstein K.A., Lang J.M., Wang L, & Dehm S.M. (2017). Androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(16), 4704-4715.